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Introduction The recent EAS consensus paper on familial hypercholester-
olæmia (FH) indicates a higher prevalence of elevated LDL-C due to genetic
reasons than previously estimated. We aimed to determine the percentage of
patients with very high LDL-C levels in the DYSIS study.
Methods The cross-sectional, observational study DYSIS examined lipid
goal attainment among statin-treated patients in Canada, Europe, the Middle
East, Egypt and South Africa. In this analysis we evaluated DYSIS patients to
determine very high LDL-C with potential genetic background. We examined
the number of patients with LDL-C >190mg/dl despite statin therapy, the
number of patients with possible FH (Score 3-5 according to the Dutch
Advanced Method) and the number of patients with probable FH (Score 6-8).
This score includes several parameters: first degree relative known with pre-
mature CHD and/or first degree relative with LDL-C >95th percentile
(1 point); first degree relative with tendon xanthomas or children with LDL-C
>95th percentile (2 points); the patient has premature CAD (2 points), the
patient has premature cerebral or peripheral vascular disease (1 point); the
patient has tendon xanthomas (6 points), the patient has corneal arcus below
the age of 45 years (4 points); LDL-C >330mg/dl (8 points), LDL-C between
250 and 329mg/dl (5 points), LDL-C between 190 and 249mg/dl (3 points)
and LDL-C between 155 and 189mg/dl (1 point). 
Results The prevalence of patients with LDL-C >190mg/dl despite statin
therapy was 3% (UK 0.8%, France 3.5%, Spain 4.2%). The prevalence of
patients with possible FH (Score 3-5) was 6% (UK 4.4%, France 5.9%, Spain
5.7%). The prevalence of patients with probable FH (Score 6-8) was 0.3%
(UK 0%, France 0.1%, Spain 0.2%).
Conclusions In this multinational study of statin-treated patients, 2.9%
showed an elevated LDL-C above 190mg/dl. Genetic causes may explain the
very high LDL-C levels despite statin therapy in the DYSIS study. 
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EZE cohort was a 48-month prospective, nationwide study conducted
between 2008 and 2013 in Franceat the request of the French Haute Autorité
de Santé. Its objective was to assess the real life use and impact of the drug
on lipid lowering. Over 700 physicians (94% general practitioners and 4% car-
diologists recruited and described 3,395 eligible adult patients who had initi-
ated ezetimibe treatment for no longer than three months, of which 3,215
(94.7%) were entered in the analyses. Patients were naturalistically followed
up to 4 years without any visits formally planned. Blood lipids were reported
by physicians every twelve months and lipid lowering medicines utilization
every six months with patient’s telephone interviews between each physician’s
visit. 
9 314 person-years of follow-up were accumulated. At inclusion, patients
were 61.5 year-old on average (standard deviation (SD): 10.7) and 54.6%
were males. Classified by CV risk categories were for primary prevention
29.3% low, 32.4% moderate and 11.4% high, and 26.9% secondary preven-
tion. 
Type of ezetimibe exposure at inclusion was 33.1% monotherapy, 13.2%
ezetimibe added to a statin, and 53.7% fixed association ezetimibe – simvas-
tatin. Exposure to ezetimibe has been very stable during follow-up of the
cohort with treatment interruption rate of 12.5 per 100 person-years of follow-
up. LDL-C was 4.1mmol/L (SD: 1.1) at baseline and decreased by 23.8% (SD:
28.8) in the first 12 months, reaching –27.3% (SD: 28.3) at 48 months.
Adjusting for baseline clinical characteristics and risk factors, interruption of
lipid lowering treatment at least once during the follow-up was associated
with a lower probability for the LDL-C to progress to the lower tertile (OR:
0.38, 95% confidence interval: 0.31 – 0.45). In this population with incident
exposure to ezetimibe LDL-C decreased by one quarter in the first year and
remained stable over the four-year follow-up.
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Background Heterozygous Familial Hypercholesterolemia (HeFH) is a
severe autosomal dominant disease which is under-diagnosed. The prevalence
of HeFH has rarely been assessed in an unselected sample from the general
population.
Methods Based on a huge sample of lipid panels, we assessed the preva-
lence of individuals classified with definite or probable HeFH (Dutch Lipid
Clinic Network (DLCN) criteria) >5 that is to say LDL-cholesterol (LDL-C)
>6.5mmol/L (251mg/dL). From 2006 to 2015, 200 620 LDL-C were obtained
from 105 398 subjects in a large database of a French University Hospital.
Subjects from 0 to 102 years (53.7±20.5) and of both genders were analysed.
LDL-C levels were calculated with the Friedewald or the Planella formula if
elevated triglycerides. We also assessed the prevalence of all DLCN LDL-C
criteria: 4.0-4.9mmol/L (155-190mg/dL); 5.0-6.4mmol/L (191-250mg/dL);
6.5-8.4mmol/L (251-325mg/dL); >8.5mmol/L (>325mg/dL).
Results The prevalence of LDL-C between 4.0 and 4.9mmol/L was 9.81%
[95% CI: 9.68-9.94]; the prevalence of LDL-C between 5.0 and 6.4mmol/L
was 2.41% [95% CI: 2.35-2.48]; the prevalence of LDL-C between 6.5 and
8.4mmol/L was 0.37% [95% CI: 0.34-0.39] and the prevalence of LDL-C
>8.5mmol/L was 0.09% [95% CI: 0.08-0.10]. In the first lipid determinations
of 105 398 subjects, the prevalence of LDL-C between 4.0 and 4.9mmol/L
was 10.77% [95% CI: 10.6-11.0]; between 5.0 and 6.4mmol/L was 2.47%
[95% CI: 2.38-2.56]; between 6.5 and 8.4mmol/L was 0.28% [95% CI: 0.25-
0.32] and of LDL-C >8.5mmol/L was 0.06% [95% CI: 0.04-0.07]. The
prevalence of definite or probable HeFH was 0.46% in 200 620 lipid determi-
nations and 0.34% in 105 398 subjects. The highest prevalence of definite or
probable HeFH was in subjects aged between 35 and 55 years.
Conclusions In France, the prevalence of definite or probable HeFH was
1/250 adults, very closed to the observed prevalence of 1/200 obtained in the
Copenhagen General Population Study.
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